TY - JOUR
T1 - Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin's lymphoma
T2 - The single-institute experience in Taiwan
AU - Hu, Yu Hui
AU - Hsiao, Liang Tsai
AU - Yang, Ching Fen
AU - Chiou, Tzeon Jye
AU - Liu, Jin Hwang
AU - Gau, Jyh Pyng
AU - Yen, Chueh Chuan
AU - Chou, Teh Ying
AU - Hsu, Wen Hu
AU - Chen, Po Min
AU - Tzeng, Cheng Hwai
PY - 2009
Y1 - 2009
N2 - Primary pulmonary lymphoma (PPL) accounts for less than 1% of patients with non-Hodgkin's lymphoma, with no report in Chinese patients. This study aims to analyze the clinical features and prognosis of this population. Patients with biopsy-proven pulmonary lymphoma were reviewed and re-classified by a hema-pathologist. Between 1992 and 2005, a total of 22 patients were identified (16 men and six women), with a mean age of 70 years. The histological subtypes included marginal zone B-cell lymphoma of mucosa-associated lymphoid tissues (MALT) in 12 patients (54%), diffuse large B-cell lymphoma in nine (41%), and one case of lymphomatoid granulomatosis. Diseases mainly manifested as pulmonary nodules or masses in 73% of patients, with a higher rate of hilar/ mediastinal lymphadenopathy in non-MALT patients (8% vs. 80%, P = 0.002). In eight patients (36% of 22), diagnoses were only conclusive until the biopsy via thoracotomy. Eighteen patients (82%) received chemotherapy. The 5-year rates of overall survival (OS) were 91% and 21% for MALT and non-MALT types of PPL, respectively. Patients who had received surgical resection tended to have a better 5-year OS rate (P = 0.077). The Cox-regression analysis showed that two factors - elevated serum lactate dehydrogenase level and hilar/mediastinal lymphadenopathy at diagnosis - were independently associated with a poor OS, with a hazard ratio of 10.370 and 5.171 (P = 0.01 and 0.033), respectively. In conclusion, the histological subtypes of Chinese PPL patients were similar to those in previous reports, with no increasing incidence of T-cell immunophenotype. The two prognostic factors provided additional information in managing these patients.
AB - Primary pulmonary lymphoma (PPL) accounts for less than 1% of patients with non-Hodgkin's lymphoma, with no report in Chinese patients. This study aims to analyze the clinical features and prognosis of this population. Patients with biopsy-proven pulmonary lymphoma were reviewed and re-classified by a hema-pathologist. Between 1992 and 2005, a total of 22 patients were identified (16 men and six women), with a mean age of 70 years. The histological subtypes included marginal zone B-cell lymphoma of mucosa-associated lymphoid tissues (MALT) in 12 patients (54%), diffuse large B-cell lymphoma in nine (41%), and one case of lymphomatoid granulomatosis. Diseases mainly manifested as pulmonary nodules or masses in 73% of patients, with a higher rate of hilar/ mediastinal lymphadenopathy in non-MALT patients (8% vs. 80%, P = 0.002). In eight patients (36% of 22), diagnoses were only conclusive until the biopsy via thoracotomy. Eighteen patients (82%) received chemotherapy. The 5-year rates of overall survival (OS) were 91% and 21% for MALT and non-MALT types of PPL, respectively. Patients who had received surgical resection tended to have a better 5-year OS rate (P = 0.077). The Cox-regression analysis showed that two factors - elevated serum lactate dehydrogenase level and hilar/mediastinal lymphadenopathy at diagnosis - were independently associated with a poor OS, with a hazard ratio of 10.370 and 5.171 (P = 0.01 and 0.033), respectively. In conclusion, the histological subtypes of Chinese PPL patients were similar to those in previous reports, with no increasing incidence of T-cell immunophenotype. The two prognostic factors provided additional information in managing these patients.
KW - Diffuse large B-cell lymphoma
KW - Lymphomatoid granulomatosis
KW - Marginal zone B-cell lymphoma
KW - Mucosa associated lymphoid tissue (MALT)
KW - Primary pulmonary non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=67849089083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67849089083&partnerID=8YFLogxK
U2 - 10.1007/s00277-008-0685-3
DO - 10.1007/s00277-008-0685-3
M3 - Article
C2 - 19139892
AN - SCOPUS:67849089083
SN - 0939-5555
VL - 88
SP - 839
EP - 846
JO - Annals of Hematology
JF - Annals of Hematology
IS - 9
ER -